Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7684A in Relapsed or Refractory Hematological Malignancies
NCT05005442Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2021
- Primary completion
- Dec 2024
- Countries
- 16
01
Overview
Phase 2, open-label trial of vibostolimab in classical Hodgkin lymphoma (cHL), primary mediastinal large B-cell lymphoma (PMBCL), follicular lymphoma (FL) and 3 more, sponsored by Merck & Co. Primary endpoints: Percentage of Participants With a Dose-Limiting Toxicity at 6 weeks, Percentage of Participants Who Experienced an Adverse Event at 27 months and 1 more. Started Sep 2021; status: completed.
02
Drugs
vibostolimab
03
Conditions
classical Hodgkin lymphoma (cHL)primary mediastinal large B-cell lymphoma (PMBCL)follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05005442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05005442.